EGR2 and neoplasm: For CRC187, the final tumor masses of KLF14‐shRNA1, KLF14‐shRNA2, EGR2‐shRNA1, and EGR2‐shRNA2 were 2.84‐, 2.18‐, 2.87‐, and 1.90‐fold higher than control PDOX, respectively (Figure 3G).